Patents by Inventor Tracy A. Willson
Tracy A. Willson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080274973Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: July 1, 2008Publication date: November 6, 2008Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Publication number: 20080166730Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: October 23, 2007Publication date: July 10, 2008Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 7279557Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: November 17, 2004Date of Patent: October 9, 2007Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 7220828Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: March 10, 1998Date of Patent: May 22, 2007Assignee: Zenyth Operations Pty LtdInventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Jian-Guo Zhang, Alison Farley, Warren Alexander, Steven Rakar, Yasufumi Kikuchi, Tetsuo Kojima, Masatsugu Maeda, Louis Fabri, Andrew Nash
-
Publication number: 20060294608Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: August 24, 2006Publication date: December 28, 2006Applicant: Zenyth Operations Pty LtdInventors: Douglas Hilton, Nicos Nicola, Alison Farley, Tracy Willson, Jian-Guo Zhang, Warren Alexander, Steven Rakar, Louis Fabri, Tetsuo Kojima, Masatsugu Maeda, Yasufumi Kikuchi, Andrew Nash
-
Publication number: 20060242718Abstract: The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associate therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signaling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.Type: ApplicationFiled: April 10, 2006Publication date: October 26, 2006Inventors: Tracy Willson, Richard Simpson, Alison Farley, Sandra Nicholson, Jian Zhang, Manuel Baca, Nicos Nicola, Douglas Hilton, Warren Alexander, Donald Metcalf
-
Patent number: 7049418Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: July 19, 2001Date of Patent: May 23, 2006Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20060003377Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: August 29, 2005Publication date: January 5, 2006Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas Hilton, Warren Alexander, Elizabeth Viney, Tracy Willson, Rachael Richardson, Robyn Starr, Sandra Nicholson, Donald Metcalf, Nicos Nicola
-
Publication number: 20050208521Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: ApplicationFiled: November 17, 2004Publication date: September 22, 2005Inventors: Douglas Hilton, Warren Alexander, Elizabeth Viney, Tracy Willson, Rachael Richardson, Robyn Starr, Sandra Nicholson, Donald Metcalf, Nicos Nicola
-
Patent number: 6911530Abstract: The present invention relates generally to a novel haemopoietin receptor or components or part thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: GrantFiled: October 13, 2000Date of Patent: June 28, 2005Assignee: Amrad Operations, Pty., Ltd.Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 6905842Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: October 31, 1997Date of Patent: June 14, 2005Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 6870031Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: GrantFiled: December 7, 2001Date of Patent: March 22, 2005Assignee: Amrad Operations Pty. Ltd.Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
-
Publication number: 20050004015Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: ApplicationFiled: December 7, 2001Publication date: January 6, 2005Inventors: Douglas Hilton, Tracy Willson, Timothy Gainsford, Warren Alexander, Donald Metcalf, Ashley Ng, Nicos Nicola
-
Publication number: 20020147307Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction.Type: ApplicationFiled: July 19, 2001Publication date: October 10, 2002Inventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Publication number: 20020090682Abstract: The present invention relates generally to a novel haemopoietin receptor or components or parts thereof and to genetic sequences encoding same. The receptor molecules and their components and/or parts and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: November 7, 2001Publication date: July 11, 2002Inventors: Tracy Willson, Nicos A. Nicola, Douglas J. Hilton, Donald Metcalf, Jian Guo Zhang
-
Patent number: 6414128Abstract: The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.Type: GrantFiled: September 17, 1998Date of Patent: July 2, 2002Assignee: Amrad Operations Pty. Ltd.Inventors: Douglas James Hilton, Tracy Willson, Timothy Gainsford, Warren S Alexander, Donald Metcalf, Ashley Ng, Nicos A Nicola
-
Publication number: 20020045741Abstract: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.Type: ApplicationFiled: March 10, 1998Publication date: April 18, 2002Inventors: TRACY WILLSON, NICOS A. NICOLA, DOUGLAS J. HILTON, DONALD METCALF, JIAN GUO ZHANG
-
Patent number: 6323317Abstract: The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.Type: GrantFiled: April 30, 1999Date of Patent: November 27, 2001Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Douglas J. Hilton, Warren S. Alexander, Elizabeth M. Viney, Tracy A. Willson, Rachael T. Richardson, Robyn Starr, Sandra E. Nicholson, Donald Metcalf, Nicos A. Nicola
-
Patent number: 5443825Abstract: Leukemia-inhibitory factor (LIF) has been produced in essentially pure form from murine or human sources. A method of purifying this LIF is disclosed, as well as polypeptides having LIF activity which are not identical in amino acid sequence to any naturally occurring form of LIF. The polypeptides can be used for hindering the proliferation of myeloid Leukemia cells.Type: GrantFiled: September 22, 1992Date of Patent: August 22, 1995Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson
-
Patent number: 5427925Abstract: The present invention provides a method for producing recombinant leukemia inhibitory factor (LIF) by the expression, in suitable host cells, of recombinant DNA molecules encoding LIF.Type: GrantFiled: May 6, 1993Date of Patent: June 27, 1995Assignee: Amrad Corporation LimitedInventors: David P. Gearing, Nicholas M. Gough, Douglas J. Hilton, Julie A. King, Donald Metcalf, Edouard C. Nice, Nicos A. Nicola, Richard J. Simpson, Tracy A. Willson